Composite hemangioendothelioma (CHE) is the most recently described vascular neoplasm of low-malignant potential, showing varying combinations of benign angiomatous lesions, and different subtypes of hemangioendothelioma and angiosarcoma. [@b1-asm-2-182] CHE mainly presents as dermal uni- or multinodular lesion on distal extremities of young to middle-aged adults, with a slow evolution, relatively high local recurrence rate, and low metastatic potential.[@b1-asm-2-182],[@b2-asm-2-182] On the whole, only 22 cases of CHE have been reported so far in cutaneous and/or subcutaneous localization.[@b1-asm-2-182],[@b3-asm-2-182]--[@b13-asm-2-182] We report a new case of cutaneous CHE, situated in previously undescribed localization of the gluteal region, with a detailed review of the published reports.

CASE
====

A 58-year-old man presented with a slowly enlarging palpable cutaneous mass in the right gluteal region, first noticed several years before. The lesion was a subcutaneous nodule measuring approximately 30 mm in greatest diameter. A complete surgical excision was performed. Grossly, the excised specimen measured 58×31×22 mm and contained a subcutaneous bluish-purple circumscribed nodule, 27 mm in diameter.

Histological examination revealed a vascular neoplasm situated mainly within the deep dermis and the subcutaneous fat tissue ([Figure 1](#f1-asm-2-182){ref-type="fig"}).

The tumor consisted of several angiomatous components that merged with each other. The predominant vascular lesion corresponded to retiform hemangioendothelioma (RHE), occupying approximately 45% of the tumor. Other histological patterns included the areas consistent with sinusoidal hemangioma (25%), arteriovenous hemangioma (10%), and angiosarcoma (20%). Areas resembling RHE were composed of long arborizing thin-walled blood vessels, extending between collagen bundles in a retiform pattern. ([Figure 2](#f2-asm-2-182){ref-type="fig"}). A component showing histological features of sinusoidal hemangioma was characterized by closely packed, thin-walled, interconnecting vascular channels lined with bland endothelium without mitotic activity ([Figure 3](#f3-asm-2-182){ref-type="fig"}). Tumor areas consistent with the arteriovenous hemangioma displayed collections of large, thick-walled vessels running from the upper dermis to the subcutaneous fat ([Figure 4](#f4-asm-2-182){ref-type="fig"}). Angiosarcomatous component showed irregular vascular channels with a complex dissecting and anastomosing growth pattern and frequent intraluminal thrombosis. Several foci of necrosis were present. Endothelial cells exhibited mild-to-moderate nuclear atypia and mitoses: mean 10 per 10 high-power fields (HPFs) with up to 5 mitoses/HPF in the most mitotically active areas ([Figure 5](#f5-asm-2-182){ref-type="fig"}).

Endothelial cells within all components of the tumor were immunohistochemically positive for factor VIII-related antigen (Clone F8/86, Dilution 1:25, Dako, Glostrup, Denmark), CD34 (Clone QBEnd10, 1:25, Dako), and CD31 (Clone JC/70A, 1:20, Dako) and negative for D2-40 (Clone D2-40, 1:200, Dako) and GLUT-1 (Polyclonal, 1:200, Lab Vision, Fremont, CA). Ki-67 (MIB-1, 1:25, Dako) labeling index was 21% in the angiosarcomatous component, 1.2% in the retiform HE, and 0% in the sinusoidal hemangioma.

Histological and immunohistochemical findings were consistent with a diagnosis of CHE. No recurrent disease was noted 3 months after the surgery. The patient was then lost for follow-up.

DISCUSSION
==========

CHE is the most recently described vascular neoplasm in the realm of the hemangioendothelioma,[@b1-asm-2-182] included in the 2002 WHO classification of tumors of soft tissue and bone.[@b2-asm-2-182] CHE is defined as a locally aggressive, rarely metastasizing neoplasm with vascular differentiation, containing an admixture of histologically benign, intermediate, and malignant components that merge with each other and vary in their relative proportions.[@b2-asm-2-182]

After the first report of Nayler et al. that included 7 cutaneous CHE cases and 1 in the extracutaneous localization,[@b1-asm-2-182] only 15 additional tumors occuring in the skin/subcutis have been reported so far.[@b3-asm-2-182]--[@b13-asm-2-182] The clinical and histopathological features of these cases in addition to our example are shown in [Table 1](#t1-asm-2-182){ref-type="table"}.

The ratio of females to males affected was 2.7:1. The age at presentation ranged from 8 to 75 years (mean, 39 years). In 3 patients, CHEs were present from birth.[@b3-asm-2-182],[@b7-asm-2-182]

Previously reported CHEs presented as poorly circumscribed single or multinodular (multicentric) lesions on distal extremities, mostly on hands and feet. Two tumors were situated on the thigh and 1 on the back and in axilla, each. CHE in our patient was localized in the skin of the, previously unreported, gluteal region. In the majority of patients, the preoperative duration of CHEs was long (mean, 16 years; range, 1.5--60 years), and in only 5 patients CHEs developed more rapidly within several months.[@b1-asm-2-182],[@b5-asm-2-182],[@b6-asm-2-182],[@b9-asm-2-182],[@b13-asm-2-182] Individual tumors measured 8 mm to 300 mm in size (mean, 50.6 mm and median 31 mm).

Within the histological components of CHEs, the most frequent were retiform HE and epithelioid HE, occurring in 91%, (20/22)[@b1-asm-2-182],[@b3-asm-2-182],[@b4-asm-2-182],[@b6-asm-2-182]--[@b13-asm-2-182] and 86% (19/22)[@b1-asm-2-182],[@b3-asm-2-182]--[@b10-asm-2-182],[@b12-asm-2-182],[@b13-asm-2-182] of patients, respectively. The present case was also characterized by the dominant component of retiform HE, occupying approximately 45% of the tumor. Areas similar to angiosarcoma were identified in 54.5% (12/22) of all cases,[@b1-asm-2-182],[@b3-asm-2-182],[@b6-asm-2-182],[@b7-asm-2-182],[@b9-asm-2-182],[@b10-asm-2-182] occupying from less than 1% to 5% when stated.[@b3-asm-2-182],[@b6-asm-2-182],[@b9-asm-2-182] The angiosarcomatous component was more widespread in the CHE reported by Tejera-Vaquerizo et al[@b10-asm-2-182] and in our case, forming 20% of the tumor; nevertheless no recurrent tumor was noted after 30 months and 3 months, respectively.

Tumor necrosis was not present in the cases of Nayler et al,[@b1-asm-2-182] and its existence was not mentioned in other CHEs at all except in the gross description of the case of Chu et al.[@b6-asm-2-182]

Data regarding the mitotic activity in cutaneous CHE are scarce. Mitoses were noted mainly in the angiosarcoma areas, ranging from few mitoses[@b1-asm-2-182] to 3 to 10 mitoses/10 HPF,[@b1-asm-2-182],[@b6-asm-2-182],[@b10-asm-2-182] similarly to the present case that exhibited 10 mitoses/10 HPF. In the retiform HE component of our case, no mitoses were seen as in the other cases.[@b1-asm-2-182],[@b6-asm-2-182],[@b11-asm-2-182] Exceptionally, Reis-Filho et al recorded 3 mitoses/mm^2^ in the retiform HE, in addition to 6 mitoses/mm^2^ within the epithelioid HE-component.[@b3-asm-2-182]

Most frequent benign vascular component was the spindle cell hemangioma, found in 14/21 (67%) cases,[@b1-asm-2-182],[@b3-asm-2-182]--[@b12-asm-2-182] followed by cavernous hemangioma in 4/21 (19%) cases,[@b3-asm-2-182],[@b6-asm-2-182],[@b7-asm-2-182],[@b9-asm-2-182] and arteriovenous malformation and lymphangioma in 3/21 (14%) each.[@b1-asm-2-182],[@b6-asm-2-182],[@b7-asm-2-182] We describe the sinusoidal hemangioma as a benign vascular component of CHE for the first time. Sinusoidal hemangioma is considered to be a variant of cavernous hemangioma, [@b14-asm-2-182],[@b15-asm-2-182] or an uncommon benign vascular tumor with some similarities to a venous malformation ("cavernous hemangioma").[@b16-asm-2-182]

Immunohistochemically, all of the previous cutaneous CHEs expressed 1 or more endothelial markers. [@b1-asm-2-182],[@b3-asm-2-182]--[@b13-asm-2-182] Our case was also positive for CD31, CD34, and factor VIII--related antigen but negative for lymphatic endothelial marker D2-40, like the cases of Fukunaga et al[@b7-asm-2-182] Variable immunopositivity for D2-40, observed in retiform HE component,[@b12-asm-2-182],[@b13-asm-2-182] and positive immunoreactivity for Prox-1 antibody, seen in epithelioid HE component,[@b8-asm-2-182] supported a lymphatic line of differentiation in these cases.[@b8-asm-2-182],[@b12-asm-2-182] HE component[@b8-asm-2-182] supported a lymphatic line of differentiation in these cases. [@b8-asm-2-182],[@b12-asm-2-182] Ki-67 proliferation index has been cited in only 2 reports of CHEs[@b6-asm-2-182],[@b8-asm-2-182] with up to 42% in angiosarcomatous component[@b6-asm-2-182] and 50% in the areas of epithelioid hemangioendothelioma.[@b8-asm-2-182] In our case, angiosarcoma component exhibited Ki-67 positivity in 21% of cells, while in the areas of retiform HE and sinusoidal hemangioma, Ki-67 index was 1.2% and 0%, respectively, reflecting the differences in proliferative activity of various CHE components.

Regarding the biological behavior of CHE, follow-up data were available in 18 of 22 cases of cutaneous tumors reported previously. Eight patients (44%) were free of the disease,[@b1-asm-2-182],[@b3-asm-2-182],[@b10-asm-2-182],[@b12-asm-2-182],[@b13-asm-2-182] 7 patients (39%) exhibited 1 or more recurrences or residual disease,[@b1-asm-2-182],[@b4-asm-2-182],[@b5-asm-2-182],[@b7-asm-2-182],[@b8-asm-2-182],[@b11-asm-2-182] and 3 patients (17%) developed metastatic lesions in lymph nodes, including 1 patient with additional liver, lung, and bone metastases.[@b6-asm-2-182],[@b8-asm-2-182],[@b11-asm-2-182] Therefore, 55.5% (10/18) of patients with cutaneous CHE had a recurrent and/or metastatic disease. After excisional therapy, local recurrences developed after several months to 4 years.[@b1-asm-2-182],[@b4-asm-2-182],[@b5-asm-2-182],[@b7-asm-2-182],[@b8-asm-2-182],[@b11-asm-2-182] Lymph node metastases were present either at diagnosis, [@b6-asm-2-182] or they developed after a few months[@b8-asm-2-182] or 2 years.[@b11-asm-2-182] Out of 3 CHEs that metastasized, only 1 primary tumor contained a component of angiosarcoma; nevertheless, the lymph node metastases in this case were composed only of RHE.[@b6-asm-2-182] Lymph node metastases of the other 2 cases of metastatic CHEs displayed epithelioid hemangioendothelioma[@b8-asm-2-182] and small-vessel proliferation with many eosinophils.[@b11-asm-2-182] These findings confirmed the initial view of Nayler et al that the common presence of an apparently angiosarcomatous component was not associated with a worse prognosis as expected in conventional angiosarcoma.[@b1-asm-2-182] CHE should be considered in the differential diagnosis of cutaneous vascular tumors to avoid inappropriately aggressive therapy.
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![Panoramic view of the large part of cutaneous composite hemangioendothelioma (Hematoxylin eosin, original magnification ×12.5).](asm-2-182f1){#f1-asm-2-182}

![Retiform hemangioendothelioma composed of long arborizing blood vessels with a hobnail appearance of the lining cells (Hematoxylin eosin, original magnification ×200).](asm-2-182f2){#f2-asm-2-182}

![Sinusoidal hemangioma characterized by closely packed, thin-walled interconnecting vascular channels forming a sinusoidal pattern (Hematoxylin eosin, original magnification ×100).](asm-2-182f3){#f3-asm-2-182}

![Arteriovenous hemangioma featuring collections of large, thick-walled vessels (right) set near the sinusoidal hemangioma (left) (Hematoxylin eosin, original magnification ×40).](asm-2-182f4){#f4-asm-2-182}

![Angiosarcomatous component exhibiting irregular vascular channels with mitotic figures (arrowheads) (Hematoxylin eosin, original magnification ×400)](asm-2-182f5){#f5-asm-2-182}

###### 

Clinical, histopathological, and immunohistochemical characteristics of cutaneous composite hemangioendothelioma from published cases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                        Case   Sex/Age, y   Location                            Pre-operative duration   Size, mm                     Histological components                Mitoses                       Necrosis   Immunohistochemistry                                                                                                                         Treatment and follow-up
  ---------------------------------------------- ------ ------------ ----------------------------------- ------------------------ ---------------------------- -------------------------------------- ----------------------------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nayler et al 2000[@b1-asm-2-182]               1      M/42         Foot                                12 y                     60×45×40                     SCH, EHE, AS                           SCH: 0\                       \-         Generally: cases 1--7: greater positivity for CD31 and FVIII than for CD34                                                                   NSR after 1 y
                                                                                                                                                                                                      AS: few                                                                                                                                                                               

                                                 2      F/27         Foot                                Since childhood          7--20                        SCH, EHE, RHE, AS                      SCH: 0\                       \-                                                                                                                                                      Recurrences for 4 y; excision and reexcision followed by a below-knee amputation: NSR after 6 y
                                                                                                                                                                                                      RHE: 0\                                                                                                                                                                               
                                                                                                                                                                                                      AS: few                                                                                                                                                                               

                                                 3      M/21         Finger                              Several months           2 nodules of unstated size   SCH, AVM, RHE                          SCH: 0\                       \-                                                                                                                                                      NSR after 13 y
                                                                                                                                                                                                      RHE: 0                                                                                                                                                                                

                                                 4      M/44         Finger                              Several years            10                           EHE, RHE, AS                           RHE: 0\                       \-                                                                                                                                                      NSR after 2 y
                                                                                                                                                                                                      AS: few                                                                                                                                                                               

                                                 5      F/31         Foot                                2 y                      10                           SCH, EHE, RHE, AS                      SCH: 0\                       \-                                                                                                                                                      NA
                                                                                                                                                                                                      RHE: 0\                                                                                                                                                                               
                                                                                                                                                                                                      AS: few                                                                                                                                                                               

                                                 6      F/71         Foot                                6 y                      30--40                       L, EHE, RHE, AS                        RHE: 0\                       \-                                                                                                                                                      NA
                                                                                                                                                                                                      AS: few                                                                                                                                                                               

                                                 7      M/35         Hand                                Several years            30                           EHE, RHE, AS                           RHE: 0\                       \-                                                                                                                                                      Recurrence within 4 y
                                                                                                                                                                                                      AS: 7/10\                                                                                                                                                                             
                                                                                                                                                                                                      HPF                                                                                                                                                                                   

  Reis-Filho et al, 2002[@b3-asm-2-182]          8      F/23         Forearm, hand                       Since infancy            130×130 ×70                  SCH, CAH, EHE, RHE, ASL                EHE: 6/mm^2^\                 NA         SCH, CAH, RHE, EHE: positivity for FVIII, CD31, CD34                                                                                         Below-elbow amputation: NSR after 7 y
                                                                                                                                                                                                      RHE: 3/mm^2^\                                                                                                                                                                         
                                                                                                                                                                                                      ASL: 9/mm^2^                                                                                                                                                                          

  Biagioli et al, 2005[@b4-asm-2-182]            9      F/46         Toe                                 3 y                      20×15                        SCH, EHE, RHE                          NA                            N NA       SCH, EHE, RHE: positivity for CD31; EHE, RHE: negativity for CD34                                                                            CO2 laser therapy: first recurrence after 2 y; surgical excision: local recurrence after 18 mo; resection of toes: NSR after 1 y

  Tronnier et al, 2006[@b5-asm-2-182]            10     F/73         I: Third toe\                       1.5 y\                   28×31×10\                    Tumor I: EHE\                          NA                            NA         Tumor I and III: positive for CD31, FVIII; negative for actin\                                                                               Excision: local recurrence after 20 mo
                                                                     II: Between first and second toe\   10 y\                    20×19×14\                    Tumor III: biopsy not performed\                                                Tumor IV: positive for CD31                                                                                                                  
                                                                     III: Foot\                          Few months\              NA\                          Tumor III: EHE\                                                                                                                                                                                                              
                                                                     IV: Achilles tendon                 Few months               NA                           Tumor IV: SCH                                                                                                                                                                                                                

  Chu et al, 2006[@b6-asm-2-182]                 11     F/18         Axilla                              2 mo                     60×45×40                     SCH, CAH, CH, AVM, EHE, RHE, KHE, AS   AS: 3/10\                     \+         Greater positivity for CD31 than for FVIII and CD34; VEGF in ASL; negativity for: CK, EMA; Ki-67: 8%--42% in AS, 1%--6% in HE, \<1% in HVM   Lymph node metastases (RHE) at diagnosis, bone metastases after 4 mo; chemotherapy and radiotherapy: lung, bones, and liver metastases after 2 y; AWRD
                                                                                                                                                                                                      HPF\                                                                                                                                                                                  
                                                                                                                                                                                                      RHE: mitotically inactive                                                                                                                                                             

  Fukunaga et al, 2007[@b7-asm-2-182]            12     F/39         Ankle, foot                         Since birth              300                          SCH, L, EHE, RHE, AS                   NA                            NA         Cases: 12,13,14,15 positive at least focally for 2 of the following: CD31, CD34, or FVIII; negative for D2-40                                Partial excision: AWRD

                                                 13     F/75         Thigh                               10 y                     35                           EHE, RHE                               NA                            NA                                                                                                                                                      Excision: recurrence after 27 mo

                                                 14     F/37         Upper arm                           Since birth              40                           CAH, L, AVM, A, EHE, RHE, AS           NA                            NA                                                                                                                                                      AWRD since birth

                                                 15     F/22         Foot                                3 y                      50                           EHE, RHE                               NA                            NA                                                                                                                                                      Partial excision; follow-up NA

  Requena et al, 2008[@b8-asm-2-182]             16     M/60         Leg, foot                           Since childhood          NA                           SCH, EHE, RHE                          NA                            NA         Positivity for: CD31, CD34, FVIII; EHE: positive for Prox-1; Ki-67: 50% in EHE                                                               Excision: local recurrence and lymph node metastases (EHE) after few months; lymphadenectomy and chemotherapy: AWRD after 1 y

  Utas et al, 2008[@b9-asm-2-182]                17     F/62         Forearm, hand                       4 mo                     50×90                        SCH, CAH, EHE, RHE, ASL                ASL: brisk mitotic activity   NA         Positivity for: CD31, CD34 and FVIII                                                                                                         Therapy with interferon; follow-up NA

  Tejera-Vaquerizo et al, 2008[@b10-asm-2-182]   18     F/23         Back                                2 y                      30                           SCH, EHE, RHE, AS                      AS: 10/10 HPF                 NA         Positivity for: CD31; Negativity for CD34, CK7 and S100                                                                                      Excision: NSR after 30 mo

  Aydingöz et al, 2009[@b11-asm-2-182]           19     F/48         Thigh                               2 y                      10--15                       CH, SCH, EH, RHE, KS                   None                          NA         Positivity for: CD34; Negativity for: S100, desmin and keratin                                                                               Multiple local recurrences; multiple excisions; lymph node metastases at 2 y; lymphadenectomy, broad en bloc excision with 100-mm margins, chemotherapy and radiotherapy: NSR after 2 y

  Tsai et al, 2011[@b12-asm-2-182]               20     F/23         Foot                                NA                       40                           EHE, RHE                               NA                            NA         Positivity for: CD31, CD34, FLI-1, D2-40\                                                                                                    Excision: NSR at 7 mo
                                                                                                                                                                                                                                               Negativity for:HHV8                                                                                                                          

                                                 21     M/8          Elbow                               18 mo                    16                           SCH, RHE                               NA                            NA         Positivity for: CD31, CD34, FLI-1, D2-40 Negativity for: HHV8                                                                                Excision: NSR at 48 mo

  Tateishi et al, 2012[@b13-asm-2-182]           22     F/34         Nose                                7 mo                     8×8                          EHE, RHE                               NA                            NA         Positivity for: CD31, CD34, FVIII, D2-40, VEGF\                                                                                              Treatment with electron beam: NSR at 9 mo
                                                                                                                                                                                                                                               Negativity for CAM5.2                                                                                                                        

  Present case                                   23     M/58         Gluteal region                      Several years            27                           SH, AVH, RHE, AS                       AS: 10/10\                    \+         Positivity for: CD31, CD34, FVIII\                                                                                                           Excision: NSR at 3 mo
                                                                                                                                                                                                      HPF\                                     Negativity for: D2-40, GLUT-1 Ki-67: 21% in AS, 1.2% in RHE, 0% in SH                                                                        
                                                                                                                                                                                                      RHE: 0/HPF\                                                                                                                                                                           
                                                                                                                                                                                                      SH: 0/HPF                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A: Angiomatosis, AS: angiosarcoma, ASL: angiosarcoma-like, AVH: arteriovenous hemangioma, AVM: arteriovenous malformation, AWD: alive without disease, AWRD, alive with residual disease, CAH: cavernous hemangioma, CH: capillary hemangioma, EH: epithelioid hemangioma; EHE, epithelioid hemangioendothelioma; HE, hemangioendothelioma; HPF, high power field; HVM, hemangioma/vascular malformation, KHE: Kaposiform hemangioendothelioma, KS: Kaposi sarcoma, L: lymphangioma, NA: not available, NSR: no sign of recurrence, RHE: retiform hemangioendothelioma, SCH: spindle cell hemangioma, SH: sinusoidal hemangioma.
